Work

Designing a cancer therapeutic peptide by combining the mitochondrial targeting domain of Noxa and ErbB2‐targeting moieties

Year: 2017

Type: article

Abstract: Many anticancer drugs target epidermal growth factor receptors to inhibit receptor tyrosine kinases and tumor growth. Here, we show that an ErbB2-targeting pronecrotic peptide (KWSY:MTD) selectively kills tumor cells expressing ErbB2 in vitro. An antibody against ErbB2 inhibits KWSY:MTD-induced cell death. KWSY:MTD causes membrane permeability which allows propidium iodide entry into the cytosol and the release of HMGB1 into the media, indicative of necrosis. Mitochondrial swelling occurs in response to KWSY:MTD. Moreover, in vivo analysis using a mouse model shows that KWSY:MTD partially suppressed growth in tumor tissue bearing ErbB2-expressing cells, but did not have obvious toxicity in mouse liver or kidney tissue. Taken together, KWSY:MTD has potential as an ErbB2-targeting anticancer drug.

Source: FEBS Letters

DOI: 10.1002/1873-3468.12922

Authors: Ji‐Hye Han, Junghee Park, Young‐Woo Seo, Tae‐Hyoung Kim

Institutions: Chosun University, Chonnam National University, Korea Basic Science Institute

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: Ministry of Health and Welfare